Histogenics Corporation Acquires NeoCart® Development and Commercialization Rights for Japanese Market

WALTHAM, Mass., May 10 (Korea Bizwire) — Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, announced that it has acquired the development and commercialization rights to NeoCart for the Japanese market from its long-time development partner Purpose Co., Ltd (Purpose).  This agreement is the next [...]